Volume | 3,294 |
|
|||||
News | - | ||||||
Day High | 17.08 | Low High |
|||||
Day Low | 16.87 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
SWK Holdings Corporation | SWKH | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
17.07 | 16.87 | 17.08 | 17.01 | 17.27 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
128 | 3,294 | $ 16.97 | $ 55,897 | - | 15.26 - 18.75 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:23 | 35 | $ 17.01 | USD |
SWK Holdings Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
312.58M | 12.50M | - | 44.06M | 15.89M | 1.27 | 19.68 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
SWK News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SWKH Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 17.20 | 17.74 | 16.78 | 17.38 | 6,880 | -0.19 | -1.10% |
1 Month | 17.93 | 18.0277 | 16.66 | 17.17 | 7,752 | -0.92 | -5.13% |
3 Months | 17.52 | 18.488 | 15.92 | 17.19 | 10,930 | -0.51 | -2.91% |
6 Months | 15.89 | 18.75 | 15.65 | 17.13 | 9,012 | 1.12 | 7.05% |
1 Year | 17.42 | 18.75 | 15.26 | 16.80 | 9,329 | -0.41 | -2.35% |
3 Years | 16.65 | 20.4945 | 15.26 | 17.97 | 15,146 | 0.36 | 2.16% |
5 Years | 14.00 | 20.4945 | 6.12 | 16.89 | 14,400 | 3.01 | 21.50% |
SWK Description
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment. |